Maximising the translational potential of neurophysiology in amyotrophic lateral sclerosis: a study on compound muscle action potentials
McKinnon, S.; Qiang, Z.; Keerie, A.; Wells, T.; Shaw, P.; Alix, J.; Mead, R.
Show abstract
Transgenic mouse models of amyotrophic lateral sclerosis, such as the widely used SOD1G93A mouse, enable investigation of disease mechanisms and testing of novel therapeutic interventions. However, treatments that have been considered successful in mice have often failed to translate into human benefit in clinical trials, particularly when relying on the so-called survival read-out. Compound muscle action potentials (CMAPs), are a simple neurophysiological test that measures the summation of muscle fibre depolarisation in response to maximal stimulation of the innervating nerve. CMAPs can be measured in both mice and humans and decline with motor axon loss in ALS, making them a potential translational read-out of disease progression which could help bridge the preclinical and clinical divide. Herein we assess the translational potential of CMAPs and ascertain at what time points human and mouse data aligned most closely. We extracted data from 18 human studies and compared with results generated from SOD1G93A and control mice at different ages across different muscles. We found that the relative CMAP amplitude difference between SOD1G93A and control mice in tibialis anterior and gastrocnemius muscles at 70 days of age was most similar to the relative difference between baseline ALS patient CMAP measurements and healthy controls in the abductor pollicis brevis (APB) muscle. We also found that the relative decline in SOD1G93A tibialis anterior CMAP amplitude between 70-140 days was similar to that observed in 12 month human longitudinal studies in APB. Our findings suggest CMAP amplitudes can provide a translational window, from which to make comparisons between the SOD1G93A model and human ALS patients. CMAPs are easy to perform and can help determine the most clinically relevant starting/end points for preclinical studies and provide a basis for predicting potential clinical effect sizes.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Mitochondrial genome variants associated with Amyotrophic Lateral Sclerosis and their haplogroup distribution 95%
- The Impact of Brain-Derived Neurotrophic Factor rs6265 (Val66Met) Polymorphism on Therapeutic Electrical Stimulation for Peripheral Nerve Regeneration: A Preclinical Study of Therapy-Genotype Interactions 93%
- Identification of gene fusions associated with amyotrophic lateral sclerosis 92%
Similar papers in this journal
- Skeletal muscle biomarkers of amyotrophic lateral sclerosis: a large-scale, multi-cohort proteomic study 93%
- Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis relates to lower motor neuron dysfunction 92%
- RAN translation of C9orf72-related dipeptide repeat proteins in zebrafish recapitulates hallmarks of amyotrophic lateral sclerosis and identifies hypothermia as a therapeutic strategy 92%
Similar papers in this journal
- Disrupted copper availability in sporadic ALS: Implications for CuII(atsm) as a treatment option 93%
- A novel method to assess motor planning deficits in patients with Parkinson's disease and mild cognitive impairment 92%
- Anatomical characterisation of somatostatin-expressing neurons belonging to the anterolateral system 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.